Latest Breaking News On - ஸ்ரீநிவாஸ் சாது - Page 5 : comparemela.com

Dr Reddy s Laboratories announces the launch of Ertapenem for Injection in the U S Market

Dr Reddy s Laboratories announces the launch of Ertapenem for Injection in the U S Market
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

United statesAndhra pradeshReddy ertapenemSrinivas saduMarc kikuchiGland pharma ltdDrug administrationReddy laboratories ltdTime zoneNorth america genericsGland pharmaஒன்றுபட்டது மாநிலங்களில்ஆந்திரா பிரதேஷ்ஸ்ரீநிவாஸ் சாதுமார்க் கீக்குச்சிசுரப்பி பார்மா லிமிடெட்

Dr Reddy s Laboratories launch antibiotic medication in US market

Dr Reddy s Laboratories launch antibiotic medication in US market Representative image Dr Reddy s Laboratories on Wednesday said it has launched Ertapenem for Injection, an antibiotic medication, in the US market. The newly launched drug is a therapeutic equivalent generic version of Invanz (ertapenem for injection) for injection, 1 g/vial. It is used for the treatment of infections of the abdomen, lungs, upper part of the female reproductive system, and diabetic foot. Dr Reddy s Laboratories has announced the launch of Ertapenem for Injection, 1 g/vial, approved by the US Food and Drug Administration (USFDA), the company said in a BSE filing.

United statesAndhra pradeshSrinivas saduMarc kikuchiDrug administrationNorth america genericsGland pharmaஒன்றுபட்டது மாநிலங்களில்ஆந்திரா பிரதேஷ்ஸ்ரீநிவாஸ் சாதுமார்க் கீக்குச்சிவடக்கு அமெரிக்கா ஜெநெரிக்ஸ்சுரப்பி பார்மா

Gland Pharma Q3 net rises 32% to ₹204 crore - The Hindu BusinessLine

Gland Pharma Q3 net rises 32% to ₹204 crore January 22, 2021 × Gland Pharma Limited has posted robust results for the third quarter and nine months ended December 31, 2020 with the company logging a profit of ₹204 crore up 32 per cent over ₹154 crore it posted for the corresponding third quarter last year. The pharma company posted revenues of ₹859.4 crore for the third quarter up 33 per cent over ₹645.9 crore for the corresponding quarter last fiscal. For the nine months ended December 31, the company had a profit of ₹736.6 crore, up 27 per cent over ₹578 crore of same period last year. The revenue for nine months was up 27 per cent at ₹2,575 crore as against ₹1,998 crore for same period of previous fiscal.

Andhra pradeshSrinivas saduGland pharmaGland pharma limitedFree trialHindu businesslineஆந்திரா பிரதேஷ்ஸ்ரீநிவாஸ் சாதுசுரப்பி பார்மாசுரப்பி பார்மா வரையறுக்கப்பட்டவைஇலவசம் சோதனை

Gland Pharma Ltd Q3FY21 net profit at Rs 204 10 crore

Gland Pharma Ltd Q3FY21 net profit at Rs. 204.10 crore Posted On: Gland Pharma Ltd has reported financial results for the period ended December 31, 2020. Financial Results (Q3 FY20-21) - QoQ Comparison The company has reported total income of Rs.894.54 crores during the period ended December 31, 2020 as compared to Rs.851.85 crores during the period ended September 30, 2020. The company has posted net profit / (loss) of Rs.204.10 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.218.85 crores for the period ended September 30, 2020. The company has reported EPS of Rs.12.82 for the period ended December 31, 2020 as compared to Rs.14.12 for the period ended September 30, 2020.

United statesSrinivas saduGland pharma ltdTime zonePharma ltdGland pharmaNet profitஒன்றுபட்டது மாநிலங்களில்ஸ்ரீநிவாஸ் சாதுசுரப்பி பார்மா லிமிடெட்நேரம் ஸோந்பார்மா லிமிடெட்சுரப்பி பார்மாநிகர ப்ராஃபிட்